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Imagination is more important than 
knowledge when knowledge is limited and can 
not solve important questions. Inventiveness in 
the drug design has been clumsiness in quality 
and quantity. This may be due to the ineptness 
and incapability of medicinal chemists to 
comprehend biochemistry and biology issues. 
On the other hand, biochemists, biologists, and 
pharmaceutical chemists do not possess the 
expertise to make complex organic entities. 
Hence, a team comprising of all expertise is a 
must to invoke a novel drug.
Drug discovery and development is 
expensive and time-consuming since it consists 
of many steps that start with target and lead 
discovery and end with human clinical trials. The 
estimation is that about 10-15 years are needed 
to present a new drug to the market with a cost 
of 1-1.5 billion dollars (Figure 1), (Karaman 2014 
a,b). During the recent few decades, considerable 
attention has been focused on improving the 
pharmacokinetics of existing marketed drugs, 
thus providing new organic entities capable of 
providing more e!ciency with fewer drawbacks 
than their corresponding parent drugs. Among the 
approaches that can fulfill the requirements for 
invoking therapeutics with optimum absorption, 
distribution, metabolism, and excretion (ADME) 
properties is the prodrug approach.
Figure 1. A diagram illustrating the di"erent stages in 
drug and prodrug development.
This approach is considered a well-established 
strategy with a high potential of success in 
obtaining organic moieties having a vast e!cacy 
and negligible toxicity. 
It is about a tenth of all worldwide marketed 
drugs are listed as prodrugs, and in the recent 
ten years their percentage was significantly 
increased and their share of all approved small 
molecular weight medicines reached 30%, and 
this high percentage signifies the great success of 
this approach. A prodrug is a chemically modified 
inactive agent consisting of a non-toxic promoiety 
and pharmacologically active moiety which upon 
exposure to a physiologic environment liberates 
the pharmacologically active parent drug to 
elicit its therapeutic benefits (Figure 2). Prodrugs 
are designed to undergo interconversion in 
physiologic environments via enzyme catalysis 
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or chemical reactions. In both cases, the prodrug 
interconversion rate is not controlled by the 
designer chemist but by the abundance of certain 
enzymes in the route of administration. Generally, 
the yield of interconversion by enzymes is less 
than 50% and could be varied among persons 
with di"erent ethnicity
Among the great number of prodrugs 
exist in the market are the ant rheumatic agent 
oxindole succinate, the anti-inflammatory drugs 
valdecoxib, prednisolone, and fluocinolone 
acetonide, the anti-glaucoma agent dipivefrin, 
the anticonvulsant agent progabide, the antiviral 
agent valacyclovir, the analgesic buprenorphine 
decanoate, fluphenazine decanoate to treat 
chronic schizophrenia, naltrexone ester prodrugs 
for narcotic dependence, nalbuphine ester as 
analgesic, and mestranol for birth control. 
The classical prodrug approach by which 
the intercoversion of the prodrug is achieved 
via enzyme catalysis has scored a significant 
success in reducing toxicity and increasing the 
bioavailability of many drugs. On the other hand, 
prodrugs designed to release the parent active 
drug through inter or intramolecular reaction 
without enzyme catalysis is a more advantageous 
approach since it lacks the intra-individual 
variability caused by the metabolic enzymes. 
In this editorial, we discuss a modern 
approach that implies the design of prodrugs 
that interconvert to their corresponding parent 
drugs through an intramolecular process. In 
this approach, molecular orbital and molecular 
mechanics methods are used to estimate reaction 
rates which then are correlated with experimental 
rate values. In this approach, there is no need 
for an enzyme to catalyze the process, and the 
cleavage rate of the prodrug to its parent drug 
is solely determined on the rate-limiting step of 
the process which is entirely dependent on the 
nature of the prodrug’s promoiety. 
For several decades, the extraordinary 
e!ciency of enzymes has been modeled by 
several well-known chemists and biochemists. 
Menger, Bruice, Kirby, Bender, and Jencks have 
assembled enzyme model devices that are capable 
of obtaining rates similar to that observed with 
enzyme-catalyzed reactions. Striking examples 
of such devices are those invoked by Menger, 
Kirby, and Bruice in which the extraordinary 
rate acceleration is due to covalently enforced 
proximity. For more than six decades, computational 
methods have been utilized by inorganic, organic, 
organometallic, and pharmaceutical chemists alike 
for predicting the physical, chemical, and molecular 
properties of compounds. Molecular orbital methods 
such as DFT, a semi-empirical and ab initio, and 
molecular mechanics methods have proven to be 
successful tools for the prediction of thermodynamic 
and kinetic parameters for biological moieties that 
have pharmaceutical / medicinal interest; drugs and 
prodrugs (Karaman 2011).
Figure 2: A diagram showing the prodrug concept.
Aiming to design novel prodrugs for commonly 
used drugs that su"er from reduced bioavailability or/
and bitter sensation we have used DFT and molecular 
mechanics methods to invoke the mechanisms and 
assign the factors determining the reaction rates 
in several intramolecular processes. Among these 
intramolecular reactions are: (1) cyclization reactions 
of di-carboxylic semi-esters by Bruice and Pandit, 
(2) lactonization of hydroxy-acids by Cohen and 
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Milstein and Menger, (3) proton transfer between 
two oxygen’s in Kirby’s acetals and proton transfer 
between nitrogen and oxygen in Kirby’s carboxylic 
amines, (4) proton transfer between two oxygens in 
rigid carboxylic amides by Menger et al. (5) proton 
transfer between two oxygens in N- alkylmaleamic 
acids by Kirby. The information gained from these 
studies was utilized to design an e!cient chemical 
entity to be exploited as a prodrug promoiety 
having the potential to release the parent drug in a 
programmable manner. For instance, unraveling the 
proton transfer mechanism of Kirby’s acetals has 
resulted in the design of azanucleosides’ prodrugs 
for the treatment of myelodysplastic syndromes, 
where the prodrug promoiety is linked to the 
hydroxyl group of the nucleoside. 
Furthermore, paracetamol prodrugs lacking 
the bitter sensation of the parent drug, paracetamol, 
have been through linking the hydroxyl phenolic 
group to a linker, thus inhibiting any biding with the 
bitter taste receptors. A variety of di"erent linkers 
were also studied for the design of several prodrugs 
including the anticonvulsant agent gabapentin, 
the antihypertensive agent, atenolol, the anti-
Parkinson’s agent dopamine, the anti-viral agent 
acyclovir, and the anti-malarial agent, atovaquone, 
the anti-bleeding agent, tranexamic acid, and the 
antibacterial agents, amoxicillin, and cephalexin. 
This novel approach which is relatively fast 
and with minimum cost can provide new prodrugs 
with increased bioavailability, reduced bitter 
sensation, and enhanced dissolution and membrane 
penetration (Haddad et al. 2018, Karaman 2014 c).
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